See if your patients are covered with Bausch + Lomb’s formulary tool.
Check our formulary toolZIRGAN® (ganciclovir ophthalmic gel) 0.15% is a topical ophthalmic antiviral that is indicated for the treatment of acute herpetic keratitis (dendritic ulcers).
Click here for full Prescribing Information for ZIRGAN.
ZIRGAN is a trademark of Laboratoires Théa Corporation used under license.
References: 1. Foster CS. Ganciclovir gel—a new topical treatment for herpetic keratitis. US Ophthalmic Rev. 2007;3(1):52-56. 2. ZIRGAN [package insert]. Bridgewater, NJ: Bausch & Lomb Incorporated; 2019. 3. Croxtall JD. Ganciclovir ophthalmic gel 0.15%: in acute herpetic keratitis (dendritic ulcers). Drugs. 2011;71(5):603-610.
ZIRGAN® (ganciclovir ophthalmic gel) 0.15% is a topical ophthalmic antiviral that is indicated for the treatment of acute herpetic keratitis (dendritic ulcers).
Click here for full Prescribing Information for ZIRGAN.
ZIRGAN is a trademark of Laboratoires Théa Corporation used under license.
Please choose an option below: